Ann Thanawastien, Ph.D. has more than 17 years of experience in clinical immunology, biomarker assay development, and preclinical science. She holds a Ph.D. in Molecular and Cellular Biology from Tulane University Health Sciences Center and completed postdoctoral training at Harvard Medical School. Dr. Thanawastien has led clinical serology and preclinical development programs across Phase 1 through Phase 2/3 vaccine trials with respect to assay qualification and validation, CRO selection and oversight, regulatory-compliant testing, and IND submissions. She brings translational experience bridging nonclinical and clinical development, designing and advancing assays from early preclinical research through fit-for-purpose clinical testing. She previously served as Director of Clinical Serology Assays at Hillevax, where she oversaw the assay development and validation strategy for norovirus vaccine programs, and led preclinical development at Matrivax Research & Development Corporation. Prior to joining ILiAD Biotechnologies full-time, she supported the company’s Phase 3 vaccine program as a clinical assays consultant.